SCHEMBL15575580

SCHEMBL15575580

Nc1nc2ccccc2n1C[C@H]1CCCN1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ CXCR4 P61073 1/20 0.45
▸ TP53 P04637 3/20 0.43
▸ MAPT P10636 1/20 0.43
▸ POLB P06746 2/20 0.43
▸ NOD1 Q9Y239 2/20 0.42
▸ USP2 O75604 1/20 0.42
▸ TLR8 Q9NR97 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ ITK Q08881 2/20 0.41
▸ TNF P01375 1/20 0.40
▸ CXCL8 P10145 1/20 0.40
▸ SOS1 Q07889 1/20 0.40
▸ NOD2 Q9HC29 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15574375 1.00 CYP1A2 (0.45) CYP1A2CYP2D6HTTCXCR4TP53
SCHEMBL15575809 0.84 PDE8B (0.46) CYP1A2CYP2D6HTTTP53MAPT
SCHEMBL15575623 0.84 PDE8B (0.46) CYP1A2CYP2D6HTTTP53MAPT
SCHEMBL15575625 0.84 PDE8B (0.46) CYP1A2CYP2D6HTTTP53MAPT
SCHEMBL16987598 0.74 ITK (0.56) HTTMAPTITK
SCHEMBL20641318 0.74 PRKACA (0.61) CYP1A2CYP2D6HTTCXCR4POLB
SCHEMBL15576004 0.74 ITK (0.55) ITK
SCHEMBL1708203 0.73 HTT (0.60) CYP1A2CYP2D6HTTCXCR4TP53
SCHEMBL979443 0.73 HTT (0.60) CYP1A2CYP2D6HTTCXCR4TP53
SCHEMBL4987672 0.73 KDM4E (0.46) NPC1ITK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2890691-B1 BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2018-04-25 — — EP disclosed
US-9573958-B2 Benzimidazole derivatives as ITK inhibitors PRINCIPIA BIOPHARMA, INC. (US) 2017-02-21 — — US disclosed
US-20150225412-A1 BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS PRINCIPIA BIOPHARMA INC. 2015-08-13 — — US disclosed
EP-2890691-A1 BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS Principia Biopharma Inc. (US) 2015-07-08 — — EP disclosed
WO-2014036016-A1 BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2014-03-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225412-A1 BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS BMX, ITK, BLK CYP1A2 3640/4885CYP2D6 2689/4885HTT 3103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback